CNS Pharmaceuticals, Inc. (CNSP) Ownership
CNSP ownership summary
as of October 18, 2026- Institutions
- 21.3% of shares outstanding
- Insiders
- 0.95% of shares outstanding
- Shares outstanding
- 1.5M
- Float
- 1.3M shares available to trade
- Short interest
- 0.06% 898 shares short
- Days to cover
- 0.19 short interest down 69.8% vs prior month
- Institutions 21.25%
- Insiders 0.95%
- Other investors 77.80%
CNSP top institutional holders
17 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Ikarian Capital, LLC | 9.29% | 136K | $658,911 | +90,000 (+196.4%) | June 30, 2026 |
| 2 | ADAR1 Capital Management LLC | 4.79% | 70K | $339,570 | +70,000 (0.0%) | June 30, 2026 |
| 3 | Stonepine Capital Management Llc | 2.84% | 42K | $201,671 | −19,427 (−31.8%) | June 30, 2026 |
| 4 | BOOTHBAY FUND MANAGEMENT, LLC | 0.93% | 14K | $65,605 | — | June 30, 2026 |
| 5 | Vanguard Fiduciary Trust Co | 0.70% | 10K | $49,606 | +10,226 (0.0%) | June 30, 2026 |
| 6 | Vanguard Capital Management, LLC | 0.48% | 6,993 | $33,923 | +6,993 (0.0%) | June 30, 2026 |
| 7 | UBS Group AG | 0.10% | 1,461 | $7,087 | +732 (+100.4%) | June 30, 2026 |
| 8 | Tower Research Capital LLC | 0.05% | 799 | $3,876 | −511 (−39.0%) | June 30, 2026 |
| 9 | Barclays PLC | <0.01% | 19 | $92 | +19 (0.0%) | June 30, 2026 |
| 10 | BARRETT & COMPANY, INC. | <0.01% | 8 | $39 | — | June 30, 2026 |
| 11 | Danske Bank A/S. | <0.01% | 1 | $5 | — | June 30, 2026 |
| 12 | DRW Securities, LLC | 0.00% | — | — | −15,429 (−100.0%) | March 31, 2026 |
| 13 | Caitong International Asset Management Co., Limited. | 0.00% | — | — | −1 (−100.0%) | June 30, 2026 |
| 14 | Citigroup Inc | 0.00% | — | — | −1 (−100.0%) | June 30, 2026 |
| 15 | Geode Capital Management, LLC | 0.00% | — | — | −23,189 (−100.0%) | June 30, 2026 |
| 16 | Mccormack Advisors International | 0.00% | — | — | −3 (−100.0%) | June 30, 2026 |
| 17 | Bank of America Corp | 0.00% | — | — | −4 (−100.0%) | March 31, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 17, 6 holders added 178K shares and 8 cut 59K.
CNSP top mutual fund and ETF holders
2 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Extended Market Index | 0.57% | 8,279 | $40,161 | −44 (−0.5%) | August 31, 2026 |
| 2 | Fidelity Series Total Market Index | 0.04% | 555 | $2,692 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
CNSP insider transactions
latest 2| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2023-08-22 | Christopher Downs | Buy | $38,100.00 | — | — |
| 2023-08-16 | John M Climaco | Buy | $54,000.00 | — | — |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
CNSP shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns CNSP
Institutional investors own 21.3% of CNS Pharmaceuticals's shares and insiders 0.95%. The largest holder is Ikarian Capital, LLC with 9.29% of the shares (136K), as of June 30, 2026. Among the top 17 institutions, 6 added shares and 8 reduced their stake in the latest filings. Short interest is 0.06% of the float, or 0.19 days of average trading volume. The share count rose 17,636.0% since 2023.
Related: CNSP analyst forecast, CNSP key metrics. See the CNSP stock overview for the latest quote and news.
CNSP ownership FAQ
Who owns the most CNS Pharmaceuticals stock?
The largest shareholders of CNS Pharmaceuticals are Ikarian Capital, LLC (9.29%), ADAR1 Capital Management LLC (4.79%), Stonepine Capital Management Llc (2.84%), BOOTHBAY FUND MANAGEMENT, LLC (0.93%), Vanguard Fiduciary Trust Co (0.70%).
What percentage of CNS Pharmaceuticals is owned by institutions?
Institutions hold 21.3% of CNS Pharmaceuticals's shares outstanding; insiders hold 0.95%.
Which funds own CNS Pharmaceuticals?
The largest fund holders of CNS Pharmaceuticals are Fidelity Extended Market Index (0.57%), Fidelity Series Total Market Index (0.04%).
What is CNS Pharmaceuticals's short interest?
898 shares of CNS Pharmaceuticals were sold short, 0.06% of the float; at the average daily volume it would take 0.19 days to cover.
Are insiders buying or selling CNS Pharmaceuticals?
Of the latest 2 reported insider transactions in CNS Pharmaceuticals (since August 16, 2023), 2 were purchases and 0 were sales.
How many shares of CNS Pharmaceuticals are outstanding?
CNS Pharmaceuticals has 1.5M shares outstanding, of which 1.3M are in the public float.